LEO Pharma presents positive new Adbry data at ADD

Privately-held Danish dermatology specialist LEO Pharma today presented positive new clinical data from the ECZTRA 6 and ECZTEND trials of Adbry (tralokinumab-ldrm) in adolescent patients aged 12 to 17 years with moderate-to-severe atopic dermatitis (AD), at the American Academy of Dermatology (AAD) 2023 Annual Meeting.

The use of Adbry in adolescent patients aged 12-17 is currently under clinical investigation and the safety and efficacy have not been fully evaluated by the US Food and Drug Administration (FDA).

“These new insights from the ECZTRA 6 study further develop our understanding of how Adbry works in adolescent patients and its effect on the spread of S. aureus colonization, a common and significant issue that can exacerbate skin infections,” said Jörg Möller, executive vice president, global R&D, at LEO Pharma. “In addition, the latest analysis of data from adolescents in the ECZTEND study shows the long-term safety and efficacy profile of Adbry. Our goal is to use these findings to better inform disease management strategies for healthcare providers and their patients,” he noted.